Biotech financial markets were buffeted by the winds of macro-economic events in 2016 ranging from the Brexit vote to the unprecedented presidential election in the US. In this new year we will take stock of what we might expect for biotech investment in 2017. Venture capitalists, corporate VCs, crossover investors and I-bankers share their outlooks for the coming year.
Moderator: Ellen B. Corenswet – Covington & Burling LLP
- Gabriel Cavazos – Leerink Partners LLC
- Marian T. Nakada – Johnson & Johnson Innovation – JJDC
- Art Pappas – Pappas Ventures
- Brian Rosenzweig – Covington & Burling LLP